Metastatic uveal melanoma research hub
7 indexed studies · 4 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients
This study looks at a new drug combination for adults with uveal melanoma (a rare eye cancer) that has spread to other areas of the body. Researchers want to see if combining an immunotherapy drug (pembrolizumab) with a targeted drug (lenvatinib) can help shrink tumours and control the cancer.
France - recruitingPhase I and Phase II (Integrated)- Other
Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM)
This study is looking at a new treatment called AloCelyvir for people with a type of eye cancer that has spread. It's an early stage study to see if the treatment works and how safe it is. Doctors will measure if tumours shrink and how long people live.
Spain - authorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
Germany · Italy · France - active not recruitingPHASE1, PHASE2
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
This study is testing a new drug, DYP688, for people with advanced uveal melanoma and other rare melanomas. It aims to find a safe dose and see how well it works against the cancer.
United States · Australia · France - active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This study looks at a new drug, IDE196, for certain advanced cancers that have specific genetic changes called GNAQ/11 mutations or PRKC fusions. It checks if the drug is safe and effective alone or when combined with other existing cancer drugs.
United States · Australia · Canada - recruitingPHASE2, PHASE3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
This study compares two drug combinations for advanced uveal melanoma. It looks at RP2 with nivolumab versus nivolumab with ipilimumab, for patients who haven't had these immune-boosting treatments before, to see which works better and is safer.
United States · Australia · United Kingdom